Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. Fortunately, hope is on the horizon as biopharmaceutical research companies have made tremendous strides towards understanding mental illnesses and developing innovative medicines. Today, PhRMA released a new report covering 163 medicines in development that are targeting common mental illnesses, all of which are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The promise of the pipeline is represented across a wide range of mental illnesses,